Seres Therapeutics, Inc.

MCRB · Nasdaq · SIC 2834: Pharmaceutical Preparations
182
SEC Filings

Business Summary

PART I Item 1. B usiness Overview We are a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through discovery and development of novel live biotherapeutic product, or LBP, candidates. We led the successful development and approval of VOWST, the first FDA-approved orally administered microbiome biotherapeutic and a Breakthrough Therapy designated drug, which was sold to Socit des Produits Nestl S.A., or SPN, and with certain of its affiliates, colle...

Next Earnings

Q2 FY2026 — expected 2026-08-18

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionMCRBdiscussed_in_filing Cybersecurity
topic_mentionMCRBdiscussed_in_filing Cybersecurity
topic_mentionMCRBdiscussed_in_filing Healthcare & Bio
topic_mentionMCRBdiscussed_in_filing Healthcare & Bio

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-122025-12-310001193125-26-103276EDGAR108K words
2025-03-132024-12-310000950170-25-038427EDGAR—
2024-03-052023-12-310000950170-24-025464EDGAR—
2023-03-072022-12-310000950170-23-006374EDGAR—
2022-03-012021-12-310000950170-22-002435EDGAR—
2021-03-022020-12-310001564590-21-010057EDGAR—
2020-03-022019-12-310001564590-20-008002EDGAR—
2019-03-062018-12-310001564590-19-006423EDGAR—
2018-03-082017-12-310001564590-18-004830EDGAR—
2017-03-162016-12-310001564590-17-004551EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-052025-09-300001193125-25-266011EDGAR67K words
2025-08-062025-06-300000950170-25-103611EDGAR—
2025-05-072025-03-310000950170-25-065173EDGAR—
2024-11-132024-09-300000950170-24-126018EDGAR—
2024-08-132024-06-300000950170-24-095821EDGAR—
2024-05-082024-03-310000950170-24-055159EDGAR—
2023-11-022023-09-300000950170-23-057805EDGAR—
2023-08-082023-06-300000950170-23-039439EDGAR—
2023-05-092023-03-310000950170-23-019222EDGAR—
2022-11-022022-09-300000950170-22-021018EDGAR—
2022-08-032022-06-300000950170-22-014052EDGAR—
2022-05-042022-03-310000950170-22-007217EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-160001193125-26-108482EDGAR1K words
2026-03-120001193125-26-103034EDGAR—
2026-03-020001193125-26-085368EDGAR—
2025-11-050001193125-25-265708EDGAR—
2025-10-030001193125-25-230118EDGAR—
2025-08-060001193125-25-173985EDGAR—
2025-07-220001193125-25-162552EDGAR—
2025-05-070001193125-25-114430EDGAR—
2025-04-220001193125-25-089189EDGAR—
2025-04-140001193125-25-080185EDGAR—

182 total filings indexed. 150 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

SXTP — 60 DEGREES PHARMACEUTICALS, INC. ABT — ABBOTT LABORATORIES ABEO — ABEONA THERAPEUTICS INC. ABVC — ABVC BIOPHARMA, INC. ACAD — ACADIA PHARMACEUTICALS INC ACTU — ACTUATE THERAPEUTICS, INC. ADCT — ADC Therapeutics SA ADIL — ADIAL PHARMACEUTICALS, INC.

Company Identity

CIK0001609809
TickerMCRB
ExchangeNasdaq
SIC2834: Pharmaceutical Preparations
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: 9a78451b6d5c6f7f08b41db03d136cb7a990559e05ab2d5ae8ab9a1761fe7c7b
parent: 2835a16b7bb251036c68653fd13d19920860f3b08b6bd9f9116f997f1e6b2445
content hash: 32b49ff2063ce5183ef1847a0ae43cedc866e76efed2220d203844933bfc8136
signed: 2026-04-13T04:46:12.068Z
sources: 22 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf